<https://www.europeanpharmaceuticalreview.com/#website>
<http://schema.org/url>
<https://www.europeanpharmaceuticalreview.com/news/21063/onglyza-saxagliptin-demonstrates-no-increased-risk-for-cardiovascular-death-heart-attack-or-stroke-in-savor-cardiovascular-outcomes-trial/>